Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTMechanism of Anti-α-Synuclein ImmunotherapyDiverse molecular targets for therapeutic strategies in Alzheimer's diseaseSuccessful therapies for Alzheimer's disease: why so many in animal models and none in humans?Intravenous immunoglobulin and Alzheimer's disease: what now?Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during agingImmunotherapeutic approaches for Alzheimer's diseaseAlzheimer's disease: Unique markers for diagnosis & new treatment modalitiesVaccines, new opportunities for a new society.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process.Degenerative alterations in noradrenergic neurons of the locus coeruleus in Alzheimer's diseaseAmyloid-beta: a crucial factor in Alzheimer's disease.Slowing of EEG background activity in Parkinson's and Alzheimer's disease with early cognitive dysfunctionNovel immunological approaches for the treatment of Alzheimer's disease.Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).Microstate connectivity alterations in patients with early Alzheimer's disease.An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivoA strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease.Amyloid-β positron emission tomography imaging probes: a critical review.Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragment.Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease.What does complement do in Alzheimer's disease? Old molecules with new insights.Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's diseaseImmunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.Plant-based vaccines for Alzheimer's disease: an overview.Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Alzheimer's disease and immunotherapy: what is wrong with clinical trials?First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models.
P2860
Q26739412-B97FBE7C-723B-45FE-A5A3-597E7ED90824Q26749755-2342D9FB-017D-4394-AA90-73C26253C3D7Q26772943-7DE06C4E-11C8-4713-90C7-D15B9ACB3007Q26827193-A0C1F3D6-8FAE-4000-9EE1-585E8AFA5285Q26859305-B33FFF71-CD6E-4083-B443-77E1490AF819Q27000371-7462DC67-A2C7-4BD3-9C6C-5D189CB5F7DEQ28077869-3170CDF9-9354-463E-A9D9-F4E9F88C35A1Q28081278-7577BF9B-5522-4098-8F42-C7063DC2FD57Q28085139-499DFBE9-F5BB-46E4-A6A5-9FB57100C4EEQ30390904-D25E210D-F600-4AF4-B76D-FAAB09822AC3Q30651551-1231D5C6-E701-4611-8CA2-F131E4ED96ACQ34020079-6B74DBEC-67DB-4FAC-B35B-18177E734FCAQ34095163-3F6BC8D5-8BC3-4802-87DB-3301D27AE794Q34451907-D279210A-0104-4FB9-8FE2-ACDE0B247D38Q34531520-D7AD2EC5-3081-4471-8C49-A40C01C7CFCDQ34562675-2F8DA7F5-B80F-46B6-A604-68659A16BD26Q34566355-2BF05A6E-B184-4628-AE8B-4D6145EC8482Q36103515-91170BCA-FEEA-475E-92E7-722A7EB052B1Q36419603-C630F5AB-338A-4C3F-865C-10A36656025CQ36685236-87D81D11-1C9F-4D08-92D2-F9056C4989B8Q36768052-98754356-5939-4ED5-A6D6-606D59620584Q37086266-8C4EDD7E-3CF9-46E1-9726-B53267F5A72EQ37141684-8BAE6EF3-6793-465E-BA0D-75005F5A3D32Q37364347-C8D59548-E934-489A-9BD5-E2698775F4A5Q37364350-1DD1A2D4-E00D-427E-95F6-AFF2ECEE2274Q37368120-7FE4750D-BAE8-4B0E-979B-BEEC7ADFC14EQ37435886-9A8C38F4-C85B-4814-89D6-6827F19BAD93Q37501943-C732B305-3216-4A72-A968-467B5E3AA28CQ37530061-C1094F6B-4D22-4A6B-9713-3F0036303C94Q38079317-CD0AD9B6-65E7-4331-A766-DB139A2478E2Q38102579-CA749F0E-4B7E-4615-8F38-830907EB4AB4Q38176962-3B50F4DB-90B0-41A5-A706-11E13235215EQ38184618-616A1825-F834-43C0-8B57-61697A5EED7FQ38224958-950E8476-E2AF-4ECD-9CD1-6671593D7348Q38400601-66770FF3-F842-45B3-9301-4833A301D774Q38569669-D1F42225-078A-46D1-95E1-DD2A208F382CQ38715233-C8266B97-6209-4172-9E41-4C2EC39DCD8BQ38912275-3FFFCBE0-FA2D-463D-80F9-3244B79F49D0Q39083050-E01CA731-E29D-497C-B0EF-FD6129E90F45Q41846962-BBEB6B0E-1617-429A-B12B-9DA21386EF8D
P2860
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunotherapy for Alzheimer's ...... based immunization strategies.
@en
Immunotherapy for Alzheimer's ...... based immunization strategies.
@nl
type
label
Immunotherapy for Alzheimer's ...... based immunization strategies.
@en
Immunotherapy for Alzheimer's ...... based immunization strategies.
@nl
prefLabel
Immunotherapy for Alzheimer's ...... based immunization strategies.
@en
Immunotherapy for Alzheimer's ...... based immunization strategies.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Immunotherapy for Alzheimer's ...... -based immunization strategies
@en
P2093
Alberto Pilotto
Andrea Santamato
Antonio Greco
Davide Seripa
Giancarlo Logroscino
Vincenzo Solfrizzi
P2860
P304
P356
10.2217/IMT.11.170
P577
2012-02-01T00:00:00Z